Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart FailureThe COMPASS-HF Study
Robert C. Bourge, MD*,1,*,
William T. Abraham, MD, FACC ,2,
Philip B. Adamson, MD, FACC ,3,
Mark F. Aaron, MD ,4,
Juan M. Aranda, Jr, MD||,5,
Anthony Magalski, MD¶,
Michael R. Zile, MD#,6,
Andrew L. Smith, MD, FACC**,7,
Frank W. Smart, MD ,8,
Mark A. OShaughnessy, MD ,
Mariell L. Jessup, MD ,9,
Brandon Sparks, MS||||,10,
David L. Naftel, PhD*,
Lynne Warner Stevenson, MD¶¶,11 on behalf of the COMPASS-HF Study Group
* Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio
Oklahoma Heart Hospital, Oklahoma City, Oklahoma
Tennessee Cardiovascular Research Institute at St. Thomas Hospital, Nashville, Tennessee
|| Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida
¶ Mid-America Heart Institute, Kansas City, Missouri
# Medical University of South Carolina, Charleston, South Carolina
** Crawford Long Hospital/Emory University Hospital, Atlanta, Georgia
 Morristown Memorial Hospital, Morristown, New Jersey
 Parkview Memorial, Fort Wayne, Indiana
 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
|||| Medtronic, Inc., Minneapolis, Minnesota
¶¶ Brigham and Womens Hospital, Boston, Massachusetts.
|